These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 7562433)
1. Evaluation of equations for unbound serum concentration prediction of carbamazepine and carbamazepine-10,11-epoxide in polytherapy pediatric patients with epilepsy. Kodama Y; Kuranari M; Kodama H; Fujii I; Takeyama M J Pharm Sci; 1995 Jul; 84(7):835-9. PubMed ID: 7562433 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of unbound serum carbamazepine and carbamazepine-10,11-epoxide concentration prediction methods in polytherapy adult patients with epilepsy. Kodama Y; Kuranari M; Fujii I; Kodama H; Takeyama M Am J Ther; 1996 Oct; 3(10):699-707. PubMed ID: 11862225 [TBL] [Abstract][Full Text] [Related]
3. Comparison of equations for predicting bound serum concentrations of carbamazepine and carbamazepine-10, 11-epoxide after polytherapy in patients with epilepsy. Kodama Y; Kuranari M; Kodama H; Tsutsumi K; Fujii I; Takeyama M J Clin Pharmacol; 1995 Oct; 35(10):995-1002. PubMed ID: 8568018 [TBL] [Abstract][Full Text] [Related]
4. Comparison of two binding equations for prediction of the concentration of unbound valproic acid in the serum of adult epileptic polytherapy patients. Kodama Y; Kuranari M; Kodama H; Zaizen T; Yukawa E; Fujii I; Takeyama M J Pharm Pharmacol; 1996 Oct; 48(10):1068-72. PubMed ID: 8953510 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of binding equation method for prediction of unbound serum valproic acid concentration in pediatric patients with epilepsy. Kodama Y; Kuranari M; Kodama H; Koike Y; Yasunaga F; Fujii I; Takeyama M Int J Clin Pharmacol Ther; 1995 Feb; 33(2):114-8. PubMed ID: 7757310 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of Binding Equation Method for Unbound Serum Concentration Prediction of Valproic Acid in Polytherapy Pediatric Patients with Epilepsy. Kodama Y; Kuranari M; Kodama H; Ashikari Y; Fujii I; Takeyama M Am J Ther; 1995 Feb; 2(2):106-111. PubMed ID: 11847536 [TBL] [Abstract][Full Text] [Related]
7. In vivo binding characteristics of carbamazepine and carbamazepine-10,11-epoxide to serum proteins in paediatric patients with epilepsy. Kodama Y; Tsutsumi K; Kuranari M; Kodama H; Fujii I; Takeyama M Eur J Clin Pharmacol; 1993; 44(3):291-3. PubMed ID: 8491247 [TBL] [Abstract][Full Text] [Related]
8. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy. Carlsson KC; Hoem NO; Glauser T; Vinks AA Clin Ther; 2005 May; 27(5):618-26. PubMed ID: 15978311 [TBL] [Abstract][Full Text] [Related]
9. Prediction of unbound serum valproic acid concentration by using in vivo binding parameters. Kodama Y; Kuranari M; Tsutsumi K; Kimoto H; Fujii I; Takeyama M Ther Drug Monit; 1992 Oct; 14(5):349-53. PubMed ID: 1448839 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of carbamazepine and carbamazepine-epoxide protein binding in patients undergoing epilepsy surgery. Gidal BE; Spencer NW; Maly MM; Pitterle ME Epilepsia; 1996 Apr; 37(4):381-5. PubMed ID: 8603645 [TBL] [Abstract][Full Text] [Related]
11. Carbamazepine and carbamazepine-10,11-epoxide serum concentrations in epileptic children. Furlanut M; Montanari G; Bonin P; Casara GL J Pediatr; 1985 Mar; 106(3):491-5. PubMed ID: 3973787 [TBL] [Abstract][Full Text] [Related]
12. Predictive capacity of carbamazepine pharmacokinetic parameters in a Portuguese outpatient population. Falcão AC; de Almeida AM; Leitão F; Santos J; Sales F; Caramona MM Ther Drug Monit; 1999 Apr; 21(2):224-30. PubMed ID: 10217344 [TBL] [Abstract][Full Text] [Related]
13. How suitable are currently used carbamazepine immunoassays for quantifying carbamazepine-10,11-epoxide in serum samples? Hermida J; Tutor JC Ther Drug Monit; 2003 Jun; 25(3):384-8. PubMed ID: 12766569 [TBL] [Abstract][Full Text] [Related]
14. Alpha 1-acid glycoprotein concentration and serum protein binding of carbamazepine and carbamazepine-10,11 epoxide in children with epilepsy. Contin M; Riva R; Albani F; Perucca E; Lamontanara G; Baruzzi A Eur J Clin Pharmacol; 1985; 29(2):211-4. PubMed ID: 4076320 [TBL] [Abstract][Full Text] [Related]
15. Valproic acid-induced carbamazepine-10,11-epoxide toxicity in children and adolescents. Rambeck B; Sälke-Treumann A; May T; Boenigk HE Eur Neurol; 1990; 30(2):79-83. PubMed ID: 2111243 [TBL] [Abstract][Full Text] [Related]
16. Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva. Westenberg HG; van der Kleijn E; Oei TT; de Zeeuw RA Clin Pharmacol Ther; 1978 Mar; 23(3):320-8. PubMed ID: 627139 [TBL] [Abstract][Full Text] [Related]
17. Valproic acid-carbamazepine interaction: is valproic acid a selective inhibitor of epoxide hydrolase? Svinarov DA; Pippenger CE Ther Drug Monit; 1995 Jun; 17(3):217-20. PubMed ID: 7624916 [TBL] [Abstract][Full Text] [Related]
18. Studies on the pharmacokinetics of total and free valproate in mono- and bitherapy with carbamazepine in epileptic children and adolescents. Steinborn B; Galas-Zgorzalewicz B Folia Neuropathol; 2002; 40(2):97-100. PubMed ID: 12230261 [TBL] [Abstract][Full Text] [Related]
19. Protein binding of valproic acid in Japanese pediatric and adult patients with epilepsy. Kodama Y; Kodama H; Kuranari M; Tsutsumi K; Ono S; Yamaguchi T; Fujimura A Am J Health Syst Pharm; 2002 May; 59(9):835-40. PubMed ID: 12004461 [TBL] [Abstract][Full Text] [Related]